Back to the future: Alzheimer's disease heterogeneity revisited

Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring

Volumn 1, Issue 3, 2015, Pages 368-370

  Au, Rhoda ^a   Piers, Ryan J ^a   Lancashire, Lee ^b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b THOMSON REUTERS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84940031968     PISSN: None     EISSN: 23528729     Source Type: Journal    
DOI: 10.1016/j.dadm.2015.05.006     Document Type: Editorial

References (20)

1. Sperling R.A., Karlawish J., Johnson K.A. Preclinical Alzheimer disease-the challenges ahead. Nat Rev Neurol 2013, 9:54-58.
2. Sperling R.A., Aisen P.S., Beckett L.A., Bennett D.A., Craft S., Fagan A.M., et al. Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011, 7:280-292.
3. Lim Y.Y., Maruff P., Pietrzak R.H., Ames D., Ellis K.A., Harrington K., et al. Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease. Brain 2014, 137:221-231.
4. Lim Y.Y., Pietrzak R.H., Ellis K.A., Jaeger J., Harrington K., Ashwood T., et al. Rapid decline in episodic memory in healthy older adults with high amyloid-β. J Alzheimers Dis 2013, 33:675-679.
5. Ellis K.A., Lim Y.Y., Harrington K., Ames D., Bush A.I., Darby D., et al. Decline in cognitive function over 18 months in healthy older adults with high amyloid-β. J Alzheimers Dis 2013, 34:861-871. AIBL Research Group.
6. Morris J.C., Roe C.M., Grant E.A., Head D., Storandt M., Goate A.M., et al. Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol 2009, 66:1469-1475.
7. Sadigh-Eteghad S., Talebi M., Farhoudi M. Association of apolipoprotein E epsilon 4 allele with sporadic late onset Alzheimer's disease, a meta-analysis. Neurosciences (Riyadh) 2012, 17:321-326.
8. Jefferson A.L., Hohman T.J., Liu D., Haj-Hassan S., Gifford K.A., Benson E.M., et al. Adverse vascular risk is related to cognitive decline in older adults. J Alzheimers Dis 2015, 44:1361-1373.
9. McEvoy L.K., Brewer J.B. Biomarkers for the clinical evaluation of the cognitively impaired elderly: Amyloid is not enough. Imaging Med 2012, 4:343-357.
10. Salloway S., Sperling R., Fox N.C., Blennow K., Klunk W., Raskind M., et al. Bapineuzumab 301 and 302 Clinical Trial Investigators. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med 2014, 370:322-333.
11. Doody R.S., Thomas R.G., Farlow M., Iwatsubo T., Vellas B., Joffe S., et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med 2014, 370:311-321. Alzheimer's Disease Cooperative Study Steering Committee, Solanezumab Study GroupSolanezumab Study Group.
12. Lam B., Masellis M., Freedman M., Stuss D.T., Black S.E. Clinical, imaging, and pathological heterogeneity of the Alzheimer's disease syndrome. Alzheimers Res Ther 2013, 5:1.
13. Katzman R. Internal medicine: New criteria for the diagnosis of Alzheimer's disease. West J Med 1985, 143:90-91.
14. Lehtovirta M., Soininen H., Helisalmi S., Mannermaa A., Helkala E.L., Hartikainen P., et al. Clinical and neuropsychological characteristics in familial and sporadic Alzheimer's disease: Relation to apolipoprotein E polymorphism. Neurology 1996, 46:413-419.
15. Watson W.J., Seiden H.S. Alzheimer's disease: A current review. Can Fam Physician 1984, 30:595-599.
16. McKhann G.M., Knopman D.S., Chertkow H., Hyman B.T., Jack C.R., Kawas C.H., et al. The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups of diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011, 7:263-269.
17. Chuang H.Y., Rassenti L., Salcedo M., Licon K., Kohlmann A., Haferlach T., et al. Subnetwork-based analysis of chronic lymphocytic leukemia identifies pathways that associate with disease progression. Blood 2012, 120:2639-2649.
18. Kim S., Kon M., DeLisi C. Pathway-based classification of cancer subtypes. Biol Direct 2012, 7:1-22.
19. Hofree M., Shen J.P., Carter H., Gross A., Ideker T. Network-based stratification of tumor mutations. Nat Methods 2013, 10:1108-1115.
20. Emig D., Ivliev A., Pustovalova O., Lancashire L., Bureeva S., Nikolsky Y., et al. Drug target prediction and repositioning using an integrated network-based approach. PLoS One 2013, 8:e60618.